IgA Nephropathy (Berger’s Disease): The Most Common Primary Glomerular Disease
IgA Nephropathy, also called IgAN or Berger’s Disease, is the most common form of primary glomerulonephritis worldwide. Primary glomerulonephritis means the kidney disease originates in the kidney itself. The disease does not result from systemic disease like systemic lupus erythematosus. IgA Nephropathy is characterized by deposition of IgA immune complexes in the glomeruli of the kidneys. The glomeruli are the filtering units of the kidney. IgA is an immunoglobulin, a type of antibody. IgA normally protects mucous membranes. However, in IgA Nephropathy, IgA deposits form in the glomeruli. These deposits trigger inflammation. Immune activation occurs within the glomeruli. Glomerular damage results. Progressive kidney disease develops. IgA Nephropathy affects approximately two to three million people worldwide. The disease accounts for approximately forty to fifty percent of all primary glomerulonephritis cases globally. The prevalence is highest in Asia. Asian populations have highest rates. The disease affects all ethnicities. The disease typically develops in children and young adults. Most commonly diagnosed between ages fifteen and thirty years. However, IgA Nephropathy can develop at any age. IgA Nephropathy can develop in older adults. Disease in children has different presentation. Children often have hematuria. Microscopic or macroscopic. Adults often have hematuria and proteinuria. IgA Nephropathy is caused by abnormal immune response producing IgA-dominant immune complexes. The exact trigger is unknown. Abnormal IgA production. Increased serum IgA. Altered IgA glycosylation. Underglycosylated IgA has reduced clearance. Accumulates in blood. Genetics important. Familial clustering. Some families multiple members affected. Environmental triggers possible. Infection possibly triggers IgA response. Mucosal infections. Respiratory tract. GI tract. IgA production increases. Mucosal immunity activates. IgA immune complexes form. Circulate. Deposit in glomeruli. Early diagnosis and appropriate treatment are crucial for slowing progressive kidney disease. With modern immunosuppressive and renoprotective therapies, many achieve preserved kidney function. Progressive kidney failure prevented in many. Understanding IgA Nephropathy helps with early recognition and appropriate management to prevent chronic kidney disease and end-stage renal disease.
How Do IgA Immune Complexes Cause Glomerular Damage in IgA Nephropathy?
To understand IgA Nephropathy, we need to learn about glomeruli and immune complex deposition. The kidney contains millions of nephrons. Each nephron is a functional unit. The glomerulus is the filter. Glomeruli filter waste from blood. Glomeruli reabsorb useful substances. The glomerular filtration barrier consists of three layers. Endothelial cells form inner layer. Basement membrane is middle layer. Podocytes form outer layer. Podocytes have foot processes. These interdigitate creating filtration slits. Blood is filtered through slits. Water and small molecules pass through. Large molecules and cells blocked. In IgA Nephropathy, IgA-dominant immune complexes deposit in glomeruli. IgA1 is the predominant subclass. IgA1 has unique characteristics. IgA1 has shortened O-linked glycans in the hinge region. Underglycosylated IgA1. Defective glycosylation. Affects clearance. Circulates longer. More likely to deposit. Galactose-deficient IgA. GD-IgA1. Highly abnormal. Accumulates in blood. Deposits in glomeruli. Serum IgA levels elevated. Many patients have elevated serum IgA. IgA immune complexes form. IgA binds to antigens. Immune complex formation. Circulating complexes. Deposit in glomeruli. Glomerular deposition. IgA complexes accumulate in glomerular mesangium. Mesangium is area between capillaries. IgA deposition activates complement. Alternative pathway activation. Classical pathway less common. Complement component C3 deposits. C1q usually negative. Distinguishes from lupus. IgA immune complexes activate mesangial cells. Mesangial cells are resident macrophages. Activation produces cytokines. IL-1, IL-6, TNF-alpha produced. PDGF produced. Chemokines produced. These inflammatory mediators recruit more immune cells. Macrophages infiltrate glomerulus. T cells infiltrate. More inflammation. Inflammatory cascade amplifies. Complement activation produces C5a. C5a recruits neutrophils. Neutrophils infiltrate glomerulus. Release enzymes. Produce reactive oxygen species. ROS. Free radicals. Cause tissue damage. The glomerular damage is progressive. Early disease shows IgA deposition alone. Mild inflammation. Glomeruli appear relatively normal under light microscopy. Electron microscopy shows electron-dense deposits. IgA on immunofluorescence. Progressive disease shows increasing glomerular proliferation. Mesangial proliferation. Endocapillary proliferation. Crescent formation. Crescent cells. Proliferating cells in Bowman’s space. Crescent formation indicates severe disease. Glomerular basement membrane thickening. Duplication. Splitting. Tram-track appearance. Segmental GBM damage. Podocyte injury develops. Foot process effacement. Loss of filtration slits. Loss of barrier function. Proteinuria results. Protein leaks into urine. Progressive proteinuria. Glomerulosclerosis develops. Glomerular scarring. Fibrosis. Glomeruli are permanently damaged. Loss of filtration surface. Progressive loss of glomeruli. Glomerular loss. Some glomeruli sclerosed. Nonfunctional. Progressive decline in GFR. Glomerular filtration rate declines. Kidney function declines. Tubular atrophy develops. Atubular glomeruli. Glomeruli without tubes. Non-functional. Interstitial fibrosis develops. Scarring between tubules. Progressive fibrosis. Loss of renal function. Chronic kidney disease. Progressive to ESRD. End-stage renal disease. Kidney failure. Dialysis or transplant needed. Understanding the inflammatory mechanisms has led to development of immunosuppressive and renoprotective therapies.
What Are the Main Symptoms and Signs of IgA Nephropathy?
IgA Nephropathy causes variable symptoms depending on disease severity and stage of progression. Many people are asymptomatic initially. No symptoms. Hematuria found on screening. Others have prominent symptoms. Hematuria, or blood in urine, is the hallmark. Gross hematuria. Visible blood. Cola-colored urine. Brown or red-tinged urine. Occurs especially after infections. URI. Respiratory tract infection. GI infection. Hematuria may resolve then recur. Microscopic hematuria. Not visible. Found on urinalysis. RBC casts present. RBC casts indicate glomerular origin. Proteinuria, or protein in urine. Increased protein. Usually mild initially. Progressive proteinuria. Increased amounts. Eventually nephrotic range proteinuria greater than three point five grams per day. Nephrotic syndrome can develop. Proteinuria causes urinary foam. Foamy urine. Protein in urine. Edema develops. Swelling. Face puffiness. Ankle swelling. Dependent edema. Hypoalbuminemia. Low blood albumin. From urinary losses. Increases edema. Hypoproteinemia. Low blood protein. Edema from low oncotic pressure. Hyperlipidemia. Elevated cholesterol. Elevated triglycerides. Risk of thrombosis. Venous thrombosis. PE risk. DVT risk. Hematuria may be first sign. Asymptomatic hematuria. Incidental finding on urinalysis. Screening urinalysis. Elementary school screening programs. Work screening. Insurance physicals. Hematuria leads to evaluation. Diagnosis made. Back pain may occur. Flank pain. Costovertebral angle tenderness. Pain over kidneys. During hematuria episodes. Usually mild. Abdominal pain. Mild abdominal discomfort. Upper quadrant. GI symptoms. Diarrhea. GI symptoms sometimes. Associated with infection. Respiratory symptoms. Upper respiratory infection. Preceding hematuria. Common triggering event. Cough. Nasal congestion. Sore throat. Associated with IgA activation. Fatigue. Malaise. General feeling of illness. Progressive disease. As kidney function declines. Nausea and vomiting. Uremia from kidney failure. Appetite loss. Difficulty eating. Weight loss. Progressive decline. Hypertension. Blood pressure elevation. Progressive disease. From kidney dysfunction. From fluid retention. Shortness of breath. Dyspnea. Fluid overload. Pulmonary edema. Advanced kidney disease. Difficulty exercising. Limitation from fluid overload. Edema limiting mobility. Pale appearance. Anemia. Decreased hemoglobin. From kidney disease. Reduced erythropoietin. Reduced RBC production. Pallor. Weakness. Cognitive changes. Uremia from advanced kidney disease. Difficulty concentrating. Confusion. Mental slowness. Confusion progressive. Itching. Pruritus. From uremia. Bone pain. CKD mineral bone disease. Phosphate retention. Calcium depletion. PTH elevation. Bone pain. The symptoms vary widely. Some have asymptomatic hematuria for years. Kidney function remains normal. Others progress rapidly. Kidney failure develops. Early detection of hematuria allows early diagnosis and treatment.
How is IgA Nephropathy Detected and Diagnosed?
IgA Nephropathy is definitively diagnosed through kidney biopsy with immunofluorescence microscopy showing IgA-dominant deposits. Early diagnosis is important for starting treatment. Clinical history is important. Hematuria. Especially gross hematuria after infection. Proteinuria. Elevated blood pressure. Family history of kidney disease. Physical examination findings. Hypertension. Blood pressure elevation. Edema. Swelling. Facial puffiness. Ankle swelling. Urinalysis. Hematuria. RBCs in urine. RBC casts. Indicate glomerular hematuria. Proteinuria. Protein in urine. Specific gravity. Concentration. WBC. Infection screening. Nitrites. Leukocyte esterase. Bacteria. Serum creatinine. Elevated creatinine. Indicates kidney dysfunction. Baseline assessment. Creatinine clearance or eGFR. Estimated GFR. Assessment of kidney function. Stage of CKD. BUN, or blood urea nitrogen. Elevated if kidney dysfunction. Indicator of kidney failure. Electrolytes. Sodium, potassium, chloride, bicarbonate. Usually normal unless advanced CKD. Hyperkalemia if advanced disease. Metabolic acidosis. Complete blood count. Hemoglobin. Anemia assessment. Platelets. Usually normal. White blood cells. Normal unless infection. Albumin. Serum albumin. Low if nephrotic syndrome. From urinary losses. Lipid panel. Cholesterol. Triglycerides. Elevated in nephrotic syndrome. Hyperlipidemia. Liver function tests. Usually normal. AST and ALT normal. Albumin level assesses liver function. Coagulation studies. PT/INR. Normal unless nephrotic with thrombosis. D-dimer elevated if VTE. Tissue typing. HLA typing. Research. Some associations. Complement levels. C3 and C4. Usually normal in IgAN. Normal C3 helps distinguish from MPGN or lupus. Serum immunoglobulin levels. IgA elevation. Many patients. IgG level. IgM level. ANA. Antinuclear antibody. Usually negative. Helps exclude lupus. Anti-GBM. Anti-glomerular basement membrane antibody. Negative. Distinguishes from anti-GBM disease. ANCA. Antineutrophil cytoplasmic antibody. Usually negative. Distinguishes from ANCA-associated vasculitis. Kidney ultrasound. Assesses kidney size. Usually normal or slightly enlarged. Echogenicity. Assesses for cysts. Rules out obstructive disease. Assessment for CKD. Small kidneys indicate advanced CKD. Doppler ultrasound. Assesses renal artery blood flow. Usually normal. Kidney biopsy is gold standard. Definitive diagnosis. Light microscopy shows glomerular proliferation. Mesangial proliferation. Crescent formation in severe disease. Electron microscopy shows electron-dense deposits. Subendothelial and intramembranous deposits. Immunofluorescence shows IgA-dominant deposits. IgA on immunofluorescence. C3 deposits. IgG and IgM negative or minimal. IgA dominance distinguishes IgAN. Biopsy also shows fibrosis and sclerosis. Glomerulosclerosis. Interstitial fibrosis. Tubular atrophy. Indicates severity. Oxford classification. Grades severity. Guides prognosis. Guides treatment. MEST-C score. Mesangial hypercellularity. Endocapillary hypercellularity. Segmental glomerulosclerosis. Tubular atrophy/interstitial fibrosis. Crescent formation. Scores 0-3. Higher scores worse prognosis. The combination of clinical presentation with hematuria, proteinuria, elevated creatinine, and kidney biopsy showing IgA-dominant immune deposits confirms IgA Nephropathy diagnosis. Early diagnosis allows early treatment preventing progression.
What Health Complications Do People with IgA Nephropathy Face?
People with IgA Nephropathy face progressive kidney disease and end-stage renal disease as major complications. The complications depend on disease severity and treatment adequacy. Chronic kidney disease progression is the major complication. Progressive decline in GFR. Gradual decline. Or rapid decline. Some patients decline rapidly. Kidney failure develops quickly. Others decline slowly. Kidney function stable for years. Then progressive decline. End-stage renal disease. ESRD. Advanced kidney failure. GFR less than fifteen. Kidney function severely impaired. Dialysis needed. Or transplantation needed. Dialysis. Hemodialysis. Three times weekly. Four hours per treatment. Vascular access needed. Fistula. Graft. Catheter. Peritoneal dialysis. Home dialysis. Continuous infusion. Fluid restrictions. Dietary restrictions. Anemia. Reduced hemoglobin. From reduced erythropoietin production. From kidney disease. Fatigue. Weakness. Dyspnea. Transfusion requirements. ESA therapy. Erythropoietin-stimulating agents. Hypertension. Blood pressure elevation. Common. Progressive. Increases cardiovascular risk. Requires antihypertensives. ACE inhibitor. ARB. Reduces proteinuria. Slows progression. Beta-blocker. Calcium channel blocker. Diuretic. Goal BP less than one hundred thirty slash eighty. Cardiovascular disease. Increased risk. Acute coronary syndrome. MI. Stroke. Heart failure. Chronic kidney disease accelerates atherosclerosis. Cardiovascular mortality increases. Dyslipidemia. Abnormal lipids. LDL elevated. Triglycerides elevated. HDL reduced. Statin therapy. Cardiovascular risk reduction. Bone disease. CKD mineral bone disease. Phosphate retention. Serum phosphate elevated. Secondary hyperparathyroidism. PTH elevation. Parathyroid hormone. Bone mineral density reduction. Osteoporosis. Fracture risk. Osteodystrophy. Bone pain. Vascular calcification. Soft tissue calcification. Cardiovascular calcification. Myocardial infarction risk. Cerebrovascular disease. Infections. Nephrotic syndrome complication. Infection risk increased. Edema with fluid accumulation. Infection risk. Peritoneal infections if peritoneal dialysis. Sepsis. Vaccinations important. Pneumococcal. Influenza. Hepatitis B. Uremia. Advanced kidney failure. Uremic toxins accumulate. Nausea and vomiting. Anorexia. Cognitive decline. Encephalopathy. Seizure. Pericarditis. Pericardial inflammation. Chest pain. Pericardial friction rub. Pericardial effusion. Tamponade risk. Hyperkalemia. Elevated potassium. Life-threatening arrhythmias. Peaked T-waves. Widened QRS. Ventricular fibrillation. Cardiac arrest. Dietary potassium restriction. Diuretics. Potassium-binding resins. Emergency treatment. Calcium gluconate. Insulin. Glucose. Hyperphosphatemia. Elevated serum phosphate. Contributes to secondary hyperparathyroidism. Contributes to vascular calcification. Phosphate binders. Calcium acetate. Sevelamer. Lanthanum. Metabolic acidosis. Low serum bicarbonate. Excess acid from kidney dysfunction. Sodium bicarbonate. Alkali therapy. Nephrotic syndrome complications. Massive proteinuria. Greater than three point five grams per day. Hypoalbuminemia. Low albumin. Edema. Hyperlipidemia. Lipids elevated. Cholesterol. Triglycerides. Statin therapy. Venous thrombosis. VTE risk. Hypercoagulability from nephrotic syndrome. Renal vein thrombosis. Pulmonary embolism. DVT. Anticoagulation if thrombosis. Infection risk. Reduced immunoglobulin. From urinary losses. Impaired immunity. Infection prone. Ascites. Massive fluid accumulation. Peritoneal dialysis complicated. Dyspnea. Orthopnea. Acute pulmonary edema. Respiratory failure. Without appropriate treatment, ESRD develops. With ACE/ARB, immunosuppression, good blood pressure control, many achieve preserved kidney function or slowed progression.
What Treatments Help People with IgA Nephropathy?
Treatment for IgA Nephropathy focuses on slowing glomerular inflammation and preventing progressive kidney disease. Renoprotection is the goal. Blood pressure control. ACE inhibitor or ARB. Angiotensin-converting enzyme inhibitor. Lisinopril. Enalapril. Ramipril. Angiotensin II receptor blocker. Losartan. Valsartan. Olmesartan. Reduces intraglomerular pressure. Reduces proteinuria. Slows kidney disease progression. First-line therapy. Used at high doses. ACE-I and ARB together. Not recommended. Increased hyperkalemia risk. Choose one or the other. Target blood pressure less than one hundred thirty slash eighty. Goal BP. Individualized. May need lower in proteinuria. Additional antihypertensives. Beta-blocker. Calcium channel blocker. Diuretic. Achieve BP goal. Immunosuppressive therapy. Corticosteroids. Methylprednisolone. Prednisone. Reduces glomerular inflammation. Used for active disease. High-dose IV methylprednisolone. Pulse therapy. Monthly pulses. With oral prednisone. Benefits shown. Slows progression. Particularly for progressive disease. Proteinuria reduction. Long-term outcomes improved. However, side effects. Infection risk. Hyperglycemia. Osteoporosis. Mycophenolate mofetil. MMF. Immunosuppressive agent. Used with corticosteroids. Shows benefit. Reduced progression. Proteinuria reduction. Adverse effects less than cyclophosphamide. Used increasingly. Azathioprine. Immunosuppressive agent. Some benefit. Less effective than MMF. Cyclosporine. Calcineurin inhibitor. Limited use. Tacrolimus. Calcineurin inhibitor. Some benefit. Data limited. Fish oil. Omega-3 fatty acids. Some studies show benefit. Proteinuria reduction. Disease progression slowing. However, evidence mixed. Some support use. Others show no benefit. Used as adjunctive. Tonsillectomy. For some with elevated serum IgA related to gut-associated lymphoid tissue. Or tonsillar disease. Controversial. Some improvement in some. Not standard. Fish oil with dipyridamole. Some benefit reported. However, limited evidence. Antiplatelet therapy. Aspirin. Some benefit. Antiplatelet effect. Reduces glomerular thrombosis. Used adjunctively. RAAS blockade. ACE-I or ARB. Essential. First-line. Slows progression significantly. Goal proteinuria reduction. Target less than one gram per day. Proteinuria reduction. With RAAS blockade. With immunosuppression. Proteinuria reduction correlates with better outcomes. Supportive care. Anemia management. ESA therapy. Erythropoietin-stimulating agents. Iron supplementation. Target hemoglobin. Hypertension management. Antihypertensive therapy. Multiple agents. BP control. Lipid management. Statin therapy. LDL reduction. Cardiovascular risk reduction. Bone health. Vitamin D supplementation. Calcium supplementation. Phosphate binders. Monitor kidney function. Serum creatinine. eGFR. Regular monitoring. Annually or more frequently. Adjust therapy based on progression. Early intervention. At first sign of decline. Dialysis and transplantation. For ESRD. Hemodialysis. Peritoneal dialysis. Kidney transplantation. Deceased donor. Living donor. Better outcomes than dialysis. IgA recurrence in transplant. May occur. But usually mild. With appropriate RAAS blockade, immunosuppression for active disease, blood pressure control, and renoprotection, many achieve slowed disease progression or preserved kidney function.
Living with IgA Nephropathy
Living with IgA Nephropathy requires medication compliance, regular monitoring, blood pressure control, lifestyle modifications, and psychological adjustment to a chronic progressive kidney disease. For people newly diagnosed with IgA Nephropathy, the diagnosis can bring relief and concern. Relief that the cause of hematuria or proteinuria is identified. Concern about progressive kidney disease. Fear of kidney failure and dialysis. However, understanding that effective treatments exist and progression can be slowed offers hope. Patient education about IgA Nephropathy, treatment options, disease course, and monitoring helps people understand their condition. Understanding importance of early treatment. Medication compliance is crucial. ACE-I or ARB compliance essential. Daily dosing. Consistent timing. Slows progression significantly. Immunosuppressive medications if prescribed. Corticosteroids. Mycophenolate mofetil. Compliance essential. Blood pressure control medications. Antihypertensive consistency. Regular monitoring. Kidney function testing. Serum creatinine. eGFR. Annually or more frequently. Guides treatment adjustments. Proteinuria monitoring. Urine protein. Protein-to-creatinine ratio. Target less than one gram per day. Below one gram better outcomes. Blood pressure monitoring. Home BP monitoring. Regular checks. Goal less than one hundred thirty slash eighty. More frequent checks initially. Then regularly. Urinalysis. Regular checks. Hematuria assessment. Proteinuria assessment. Complete metabolic panel. Serum electrolytes. Potassium monitoring. If on ACE-I or ARB. Hyperkalemia risk. Creatinine. BUN. Phosphate. Calcium. Lipid panel. Annually. Cholesterol management. LDL reduction. Complete blood count. Hemoglobin monitoring. Anemia management. Bone health monitoring. If advanced CKD. Phosphate and calcium monitoring. PTH monitoring. Vitamin D levels. Cardiovascular risk factors. Lipid management. BP control. Diabetes prevention. Stress management. Stress may worsen disease. Meditation and relaxation. Yoga. Regular exercise. Reduces stress. Improves cardiovascular health. Activity management. Regular moderate exercise. Low-impact. Walking. Swimming. Cycling. Protects kidney health. Avoid heavy strenuous exercise. Heavy weights. Sprinting. Increases proteinuria. Moderate exercise recommended. Nutrition management. Sodium restriction. Reduces blood pressure. Reduces proteinuria. Less than two grams daily. Hard to achieve. Less than five grams reasonable. DASH diet. Mediterranean diet. Healthy dietary patterns. Potassium management. If high potassium or on ACE-I. Avoid high-potassium foods. Bananas. Oranges. Spinach. Limit. Consistent potassium. Phosphate management. If advanced CKD. Low phosphate diet. Avoid processed foods. Avoid dairy. Limit. Protein management. Adequate protein. But not excess. High protein intake increases proteinuria. Moderate protein. Zero point eight grams per kilogram. Individualize. Fluid management. If ESRD approaching. Fluid restriction. Two liters daily. Then one liter if dialysis. Careful monitoring. Smoking cessation. Smoking increases glomerular damage. Accelerates disease. Smoking cessation crucial. Work and school adjustments. May need time for medical appointments. Regular clinic visits. Biopsies if needed. May affect work schedule. Dialysis if ESRD. Hemodialysis three times weekly. Restricts schedule. Peritoneal dialysis. More flexible. Continuous infusion. Dating and relationships. Explaining condition to partners. Disease uncertainty. Medical appointments. Medication side effects. Understanding helps. Sexual function. Usually preserved. Advanced kidney disease. Uremia. Anemia. May affect libido. Communication important. Pregnancy. Women with IgAN can become pregnant. Requires careful planning. Disease progression risk in pregnancy. Increased proteinuria. Blood pressure elevation. Hypertension management crucial. ACE-I and ARB contraindicated in pregnancy. Switch to methyldopa. Labetalol. Nifedipine. Careful monitoring throughout pregnancy. Regular renal and obstetric follow-up. Fetal monitoring. Outcomes usually good if BP well-controlled. Mental health support. Anxiety about kidney failure. Fear of dialysis. Depression possible. Counseling helps. Support groups. Others with IgAN. Share experiences. Coping strategies. Online communities. Family education. Understanding disease progression. Understanding treatment. Support with medication management. Emotional support crucial. Regular medical follow-up. Nephrology follow-up. Regular assessment. Disease progression monitoring. Treatment adjustments. With appropriate ACE-I or ARB therapy for renoprotection, immunosuppression for active disease when indicated, blood pressure control to goal, proteinuria reduction to target, lifestyle modifications, stress management, nutrition management, psychological support, family and social support, and regular monitoring, most people with IgA Nephropathy achieve slowed disease progression and maintain reasonable kidney function preventing ESRD or significantly delaying it despite the progressive nature of this glomerular disease.
Frequently Asked Questions About IgA Nephropathy
FAQ 1: Will IgA Nephropathy always lead to kidney failure? IgA Nephropathy does not always lead to kidney failure. Disease course variable. Some have asymptomatic hematuria for decades. Kidney function remains normal. Others progress to ESRD. Progression predictable somewhat. Poor prognostic factors. Heavy proteinuria. Rapid rise in creatinine. Severe glomerulosclerosis on biopsy. Crescent formation. Interstitial fibrosis. However, with modern treatment, progression can be slowed. Many preserve kidney function decades. Early treatment crucial. Slows progression significantly.
FAQ 2: Can IgA Nephropathy recur after kidney transplant? Yes, IgA Nephropathy can recur in transplanted kidney. Recurrence rate approximately fifty percent. However, usually slower than original disease. Graft loss from recurrence occurs but less common than from other diseases. Most with recurrence maintain graft function. Can live many years with transplant. Recurrence may be mild. Some have no recurrence. Early post-transplant monitoring. Proteinuria indicates recurrence. Biopsy may show recurrence. Early intervention may slow progression.
FAQ 3: Is IgA Nephropathy hereditary? IgA Nephropathy has genetic component. Familial clustering. Some families multiple members affected. However, not directly inherited in simple Mendelian pattern. Genetic predisposition. Environmental trigger necessary. Most with genetic predisposition do not develop disease. Siblings of affected. Elevated risk. Screening for hematuria. Urinalysis. Early detection if develops.
FAQ 4: What is the prognosis for IgA Nephropathy? Prognosis variable. Some maintain normal kidney function. Others progress to ESRD. At twenty years. Approximately thirty to forty percent reach ESRD. However, with modern treatment, better. ACE-I, ARB, immunosuppression. Progression slower. Preservation rates improved. Individual prognosis depends on severity at diagnosis. Proteinuria level. Creatinine level. Biopsy findings. With early treatment and good adherence. Many preserve function decades.
FAQ 5: Are there new treatments being developed for IgA Nephropathy? Yes, significant research ongoing. Complement inhibitors. C5 inhibitor. Eculizumab. Shows benefit in clinical trials. C3 inhibitor. Pegcetacoplan. Shows promise. B cell targeting. Obinutuzumab. B cell depletion. Shows benefit. Proteinuria reduction. BAFF inhibitors. B cell activation factor. Targets B cell support. JAK inhibitors. LOXL2 inhibitor. Targets fibrosis. Antifibrotic agents. Slowing progression. Gene therapy. Correcting IgA production. Experimental. Better treatments anticipated. Improved outcomes expected.
References and Further Reading
For more information about IgA Nephropathy, you can visit several trusted and authoritative sources providing detailed information for patients and families dealing with this glomerular kidney disease. The World Health Organization at WHO.int provides comprehensive information about IgA Nephropathy and primary glomerulonephritis. The National Kidney Foundation at Kidney.org offers excellent patient education and resources about kidney diseases including IgA Nephropathy. The IgA Nephropathy Support Network at IgANSupport.org provides patient education and support specifically for those with IgA Nephropathy. The American Kidney Fund at KidneyFund.org provides resources about kidney disease and financial assistance. MedlinePlus, a service of the National Library of Medicine at MedlinePlus.gov, has detailed medical information about IgA Nephropathy written in language that patients and families can easily understand without specialized medical knowledge. The five main reference links are: 1) WHO.int – IgA Nephropathy, 2) National Kidney Foundation, 3) IgA Nephropathy Support Network, 4) American Kidney Fund, and 5) MedlinePlus – IgA Nephropathy.
Disclaimer
This article adapts publicly available information from WHO’s IgA Nephropathy and primary glomerulonephritis information pages. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. If you or someone you know has been diagnosed with IgA Nephropathy or shows signs of this condition including hematuria, proteinuria, elevated serum creatinine, or progressive kidney dysfunction, please consult immediately with qualified healthcare professionals, nephrologists, and kidney specialists for proper diagnostic evaluation with urinalysis, kidney function tests, immunological markers, and kidney biopsy with immunofluorescence if indicated, and for appropriate treatment with ACE inhibitors or angiotensin II receptor blockers, immunosuppression if needed, and blood pressure control. Early diagnosis and early aggressive treatment significantly slow disease progression and prevent end-stage renal disease. Regular monitoring of kidney function is essential. For more information, visit WHO.int and ObserverVoice.com.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
